Analysis of an Expanded Targeted Early Cytomegalovirus Testing Program

Objective Determine the detection rate from an expanded targeted early cytomegalovirus (CMV) testing program implemented from a large healthcare system (Intermountain Healthcare, IHC). Study Design Retrospective review. Setting Tertiary medical center. Methods An electronic system was modified to in...

Full description

Saved in:
Bibliographic Details
Published in:Otolaryngology-head and neck surgery 2023-09, Vol.169 (3), p.679-686
Main Authors: Suarez, Daniel, Nielson, Christopher, McVicar, Stephanie B., Sidesinger, Max, Ostrander, Betsy, O'Brien, Elizabeth, Ampofo, Krow, Ling, Con Y., Miner, Lonnie J., Park, Albert H.
Format: Article
Language:English
Subjects:
CMV
congenital
cytomegalovirus
hearing loss
infection
newborn
screening
sensorineural
TORCH infection
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Determine the detection rate from an expanded targeted early cytomegalovirus (CMV) testing program implemented from a large healthcare system (Intermountain Healthcare, IHC). Study Design Retrospective review. Setting Tertiary medical center. Methods An electronic system was modified to include indications for testing whenever a provider placed an order for CMV testing. A retrospective analysis of this database was performed. Results From March 1, 2021 to August 31, 2022, there were 3450 (8.8%) patients who underwent CMV testing out of 39,245 total live births within the IHC system. Since the formal implementation of this program in 2019, annual CMV testing has increased almost 10‐fold: 2668 CMV tests were performed in 2021 compared to 289 CMV tests in 2015. The most frequent indication for congenital CMV (cCMV) testing was small for gestational age (SGA) (68.2%), followed by macrocephaly (13.5%), an abnormal hearing test (5.0%), and microcephaly (4.4%). Fourteen cCMV‐infected infants were diagnosed all of them meeting the criteria for symptomatic cCMV. The most common indication resulting in a positive diagnosis was those who presented with SGA (n = 10 patients). The positivity rate would result in a prevalence of 35.7 symptomatic cCMV cases diagnosed per 100,000 live births, numbers comparable to those expected for universal cCMV screening. Conclusion An expanded targeted early cCMV testing program may improve detection rates of symptomatic cCMV cases and should be considered as a feasible alternative approach to universal or hearing‐targeted early CMV testing.
ISSN:0194-5998
1097-6817
DOI:10.1002/ohn.320